Edoxaban, an oral anticoagulant, was equally or more effective than warfarin in reducing the risk of stroke and blood clots for patients after heart valve replacement surgery, according to ...

In the EPIC-CAD trial, edoxaban monotherapy was associated with better net clinical benefit than edoxaban plus a single antiplatelet agent, when given as long-term antithrombotic therapy, in ...

CHICAGO — For children with rare heart conditions that increase risk for thromboembolism, daily edoxaban may be a safe and effective alternative compared with the current standard of care for ...

Edoxaban monotherapy for patients with atrial fibrillation and stable coronary disease reduced risk for adverse clinical events, mainly driven by lower bleeding risk, compared with dual ...

Data from more than 13,000 patients with AF show that the use of edoxaban over four years is associated with a low annualised rate of all-cause death, ischaemic stroke and major bleeding. 1, 2 The ...

In patients with device-detected atrial high-rate episodes, treatment with edoxaban did not reduce ischemic events and increased risk for a composite of death and major bleeding compared with ...

However, major bleeding rates were lower for apixaban, driven by differences in gastrointestinal bleeding and other nonspecified bleeding (45.57 vs 31.21 per 1,000 person-years; adjusted HR 1.42 ...

Edoxaban adherence (receiving 80%-120% of prescribed doses) was 94% in the main study but dropped to 55% in the extension phase, which the authors suggest is likely because part of the study was ...

Male patients made up 51.3% and 62.4% of the edoxaban and warfarin arms, respectively. About one in five patients had AF, and the vast majority of patients had aortic valve surgery. About one-third of ...

The analysis population consisted of 2536 patients (1270 in the edoxaban group and 1266 in the placebo group). The mean age was 78 years, 37.4% were women, and the median duration of AHREs was 2.8 ...